Abbott Laboratories (ABT)

Sep 28, 2026

ADARx Pharmaceuticals is seeking to raise up to $371.9 million in a U.S. IPO, targeting a valuation of up to $1.74 billion, with significant backing from AbbVie Inc. AbbVie has agreed to invest up to $100 million in a concurrent private placement, giving it a 4.9% stake, and previously collaborated with ADARx with a $335 million payment. While ADARx has multiple programs, including a late-stage candidate onvuzosiran, the IPO's success hinges on investors' willingness to value experimental medicines given the selective biotech IPO market.

Sep 28, 2026

A Pennsylvania woman has filed a lawsuit against Abbott Laboratories and Abbott Medical, claiming their spinal cord stimulation devices are defective and caused her worsening pain and neurological injuries. The lawsuit alleges that the devices' leads and implantable pulse generators have high failure rates, leading to complications like lead fractures, insulation breaches, and uncontrolled electrical stimulation that can cause permanent nerve damage. The plaintiff asserts that Abbott representatives downplayed risks and recommended reprogramming instead of device removal, leading to prolonged harm.

Sep 28, 2026

Johnson & Johnson, through its DePuy Synthes subsidiary, has introduced three new orthopedic trauma products that aim to automate and improve fracture treatment. These innovations include the MAXFRAME AUTOSTRUT Bluetooth version automatic external fixation system, an expanded VOLT plate system with MOSAIC technology for better anatomical fit, and the upcoming VELYS Trauma AI intraoperative AI system. These products represent a shift towards automated execution, improved implantation, and enhanced guidance in fracture care, addressing the limitations of manual methods and potentially transforming the business model from one-time sales to subscription-based services.

Sep 27, 2026

This article compares Gilead Sciences (GILD) and Abbott Laboratories (ABT) as dividend healthcare stocks, highlighting their differing risk-reward profiles. Gilead offers stronger current growth, particularly in its HIV franchise, but carries concentration risk and high R&D spending for diversification. Abbott, while growing slower, boasts a more diversified business across medical devices, diagnostics, and nutrition, along with a long history of consistent dividend increases.

Sep 24, 2026

Truist has initiated a Buy rating for MiniMed Group (MMED) with a $29 price target, citing a turnaround driven by increased investment, an improved business strategy, and new product launches. The analyst notes that MiniMed is benefiting from these factors following a period of under-investment by Medtronic (MDT).

Sep 24, 2026

Abbott Laboratories (ABT) is facing significant headwinds due to slow recovery in its Nutrition segment and intensifying competition in its Structural Heart and Continuous Glucose Monitor businesses, according to Tributary Capital Management's Q2 2026 investor letter. Despite these challenges, Citi believes ABT shares are undervalued relative to its business segments. However, the company's stock has declined by 7.27% over the past month and 22.37% over the last 52 weeks, with a current market capitalization of $179.08 billion.

Sep 24, 2026

Abbott Laboratories (ABT) is facing challenges with slow recovery in its Nutrition segment and increased competition in its Structural Heart and Continuous Glucose Monitor businesses. Despite these headwinds, the company is experiencing a tailwind in Electrophysiology. An investor letter from Tributary Capital Management highlighted these concerns, while noting that AI advancements are reshaping the investment landscape, and Citi believes ABT shares are undervalued relative to its business segments.

Sep 24, 2026

A U.S. FDA advisory panel has voted that the benefits of Grail's Galleri blood-based cancer detection test outweigh its risks, moving it closer to potential approval. The panel endorsed the test's safety and its ability to detect difficult cancers in adults aged 50 and older, though members were split on its effectiveness. The FDA will consider this recommendation heavily in its final decision.

Sep 23, 2026

A federal health advisory panel has endorsed Grail Inc.'s Galleri blood test for detecting signs of various cancers in healthy individuals, despite acknowledging uncertainties about its effectiveness and the need for further study. The panel voted 7-2 that the benefits outweigh the risks, paving the way for potential widespread adoption if the FDA agrees, though they stressed it should supplement, not replace, existing cancer screenings.

Sep 23, 2026

Abbott is collaborating with Berry Street to integrate personalized nutrition coaching into its Lingo continuous glucose monitor (CGM) platform. This partnership allows Lingo users to access virtual one-on-one sessions with registered dietitians, leveraging their CGM data for tailored guidance and discounts on sensors. The initiative aims to combine advanced biosensing technology with expert nutritional advice to support healthier lifestyle habits.

Sep 23, 2026

Abbott Laboratories has been given a Hold rating because its current valuation largely reflects its business quality and future growth potential. The Medical Devices segment is the primary growth driver, showing strong comparable growth, and the Exact Sciences acquisition is expected to provide future growth post-2027. However, the company's current growth remains below its full-year targets, and acceleration in comparable sales growth and clearer integration of Exact Sciences would be needed to justify its premium valuation.

Sep 23, 2026

Representative Rick Allen of Georgia sold Rollins (NYSE: ROL) stock worth between $15,001 and $50,000 on August 12, 2026, which was filed in September. This transaction is part of 81 stock trades made by Rep. Allen totaling over $2.41 million in the last three years, including significant trades in American Water Works Co and Ameriprise Finl, as well as recent sales of Abbott Laboratories (NYSE: ABT) and a purchase of Broadcom (NASDAQ: AVGO). Congressional transactions, while not primary investment advice, can offer insights into representatives' market expectations.

Sep 23, 2026

Abbott Laboratories (ABT) trades at a premium valuation compared to its faster-growing rivals, Stryker (SYK) and Boston Scientific (BSX), despite slower operating income growth. Abbott's diversified business and confident forecast support its valuation, while its peers offer more focused growth and higher margins at lower price-to-operating-income ratios. Investors face a decision between Abbott's stability and its competitors' more aggressive growth profiles, with Abbott's second-half performance critical to validating its premium.

Sep 23, 2026

An FDA advisory panel has recommended approval for Grail's Galleri blood test, the first multi-cancer detection blood test, for individuals aged 50 and over. While the test can detect up to 50 forms of cancer, concerns were raised about its effectiveness in early detection and potential for false senses of security. The panel's recommendation includes caveats for marketing materials, emphasizing that the test should supplement, not replace, standard cancer screenings.

Sep 22, 2026

Following a multi-million dollar settlement by Abbott Laboratories over alleged bacterial contamination in infant formula, there's a renewed push in New York to pass a bill setting state standards for testing baby food and infant formula. State Senator Michelle Hinchey, sponsor of the "Baby Food and Infant Formula Safety and Transparency Act," emphasizes the need for state-level regulations for heavy metals in these products, as federal guidelines are not always enforceable. Governor Kathy Hochul's office stated she will review the bill, which would also require QR code labels for chemical levels.

Sep 22, 2026

Abbott Laboratories has agreed to pay nearly $385 million to settle allegations from the Department of Justice regarding unsanitary conditions at two of its infant formula plants. These allegations were initially brought forth by whistleblowers and claimed that the facilities did not comply with federal and state regulations. The settlement addresses these long-standing concerns about manufacturing standards.

Sep 22, 2026

This article identifies three healthcare stocks—Abbott Laboratories (ABT), Summit Therapeutics (SMMT), and Novo Nordisk (NVO)—that showed significant "whale alerts" in options trading. These alerts indicate unusual options activity, which can signal potential trading opportunities for investors. The report details specific put and call options, their sentiment (bullish or bearish), expiration dates, strike prices, and trading volumes for each company.

Sep 22, 2026

GRAIL stock surged 34% after FDA staff found no major safety or accuracy issues with its Galleri cancer test, ahead of an advisory committee vote. Despite the jump, the average analyst price target of $79 is significantly below the current $108 share price, indicating the Street has not yet caught up to the market's positive reaction. The FDA's remaining questions primarily concern labeling, not the test's core validity or safety, easing investor concerns about approval.

Sep 22, 2026

Abbott Laboratories has agreed to pay $385 million to resolve state and federal civil allegations that it produced powder infant formula under unsafe conditions and made false claims. The settlement includes $348.7 million for the federal government and $35.5 million for state Medicaid programs, with California receiving over $15 million. This agreement stems from allegations between 2018 and 2022 concerning contamination risks at Abbott's Sturgis, Michigan facility, which led to a product recall and national formula shortage in 2022.

Sep 21, 2026

North Carolina has reached a settlement with Abbott Laboratories concerning the contaminated baby formula that caused a nationwide shortage in 2022. Abbott will pay $384 million to resolve Medicaid fraud allegations, with North Carolina receiving over $216,000. Regulators found that Abbott knowingly sold contaminated formula and failed to report positive bacterial test results to the FDA.

Sep 21, 2026

Grail's shares surged after FDA staff reviewers indicated no major concerns regarding the accuracy and safety of its multi-cancer blood test, Galleri. The findings are set to be discussed at an FDA external advisers' meeting, despite previous setbacks for the test in a UK trial. An FDA approval would significantly boost the test's distribution and insurance coverage.

Sep 21, 2026

This article compares the recent quarterly revenue trends of Abbott Laboratories (ABT) and Intuitive Surgical (ISRG), highlighting the investing truth that larger companies often experience slower growth rates. While Abbott Labs maintains steady baseline revenue with a dividend, Intuitive Surgical demonstrates higher growth in its core surgical revenue. The analysis suggests that both companies have solid business models, but investors should monitor Intuitive's continued growth pace and consider potential entry points given recent stock declines for both.

Sep 19, 2026

Illumina Inc. has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer. These new hires bring extensive leadership experience from the life sciences, diagnostics, and medical technology sectors, aiming to strengthen Illumina's executive team and drive continued growth and customer service.

Sep 18, 2026

Abbott Laboratories has agreed to pay over $384 million to resolve claims that it manufactured and sold infant formula with contamination risks to federal and state programs. This settlement stems from a 2022 recall of Abbott's baby formula products and a lawsuit initiated by three former whistleblower employees. The U.S. Justice Department intervened in the lawsuit last year.

Sep 18, 2026

As of January 31, 2026, the Schwab S&P 500 Index Fund, part of Schwab Capital Trust, reported total net assets of over $133.7 billion. AbbVie Inc. is the fund's largest equity holding, valued at approximately $886 million. This data provides investors with insight into the fund's significant equity exposures and portfolio allocation.

Sep 18, 2026

New York will receive over $9.3 million as part of a $384 million settlement with Abbott Laboratories. The settlement resolves allegations that Abbott failed to maintain proper safety standards at its manufacturing facilities from 2018 to 2022, leading to the sale of potentially contaminated baby formula, some of which was purchased with public assistance funds. Abbott stated that the settlement does not represent an admission of fault and that its criminal investigation by the federal government has been closed.

Sep 18, 2026

Abbott Laboratories, the maker of Similac, has agreed to a $384 million settlement over claims of unsanitary conditions at its baby formula production facilities, including one in Casa Grande. The lawsuit alleged that Abbott sold contaminated formula to government assistance programs like WIC. Although Abbott denies wrongdoing, a 2023 inspection of the Casa Grande facility found lapses in safety protocols and detections of cronobacter.

Sep 18, 2026

Abbott Laboratories has agreed to pay over $384 million to settle allegations it knowingly produced contaminated infant formula and sold it to federal and state programs. The U.S. Justice Department stated that the settlement resolves claims that Abbott was aware of contamination risks at its Michigan and Arizona plants but failed to test products properly or alert regulators. Despite the settlement, Abbott maintains it does not admit fault, and tests of unopened products linked to the 2022 recall were negative for Cronobacter sakazakii.

Sep 18, 2026

Abbott Laboratories has agreed to pay nearly $385 million to settle federal and state allegations of supplying substandard infant formula from its Sturgis plant, which led to a nationwide shortage in 2022. The U.S. Attorney's Office alleged manufacturing conditions risked microbial contamination between 2018 and 2022, mirroring earlier whistleblower complaints. Despite the settlement, Abbott maintains no admission of liability and stands by the safety of its products.

Sep 18, 2026

Abbott Laboratories has agreed to a $385 million settlement to resolve claims stemming from its Sturgis, Michigan baby formula plant. The plant's 2022 shutdown due to contamination concerns contributed significantly to a nationwide baby formula shortage. Abbott maintains the settlement does not represent an admission of fault and that government regulators did not find Cronobacter sakazakii in unopened formula from affected infants.

Sep 17, 2026

Medtronic has raised its fiscal 2027 profit and revenue outlook for the second time, driven by strong demand for cardiovascular devices and double-digit growth across all major business segments. The company reported first-quarter revenue of $9.76 billion and adjusted earnings per share of $1.45, both exceeding analyst expectations. While new partnerships and product launches fuel optimism, Medtronic faces challenges including tariff headwinds and uncertainty surrounding the potential separation of its diabetes business.

Sep 17, 2026

Johnson & Johnson is exiting the left atrial appendage (LAA) closure market, selling the assets of its Laminar technology to Jaguar LAA, a newly formed private company. The move follows J&J's suspension of a pivotal trial for the Laminar device due to potential post-implant unwrapping and leaks. Jaguar, formed in partnership with Santé Ventures and Laminar's management, plans to continue developing the differentiated LAA closure technology.

Sep 17, 2026

Abbott Laboratories has agreed to pay over $384 million to resolve allegations of submitting false claims to federal and state programs related to powdered infant formula and nutritional therapy products. The settlement includes $348.7 million for the federal government and $35.5 million for participating states, including New Jersey. The allegations stem from manufacturing issues at Abbott's facilities where products were made under conditions that risked microorganism contamination.

Sep 16, 2026

Michigan will receive nearly $470,000 as part of a $384.7 million national settlement with Abbott Laboratories. The settlement addresses allegations that Abbott violated the False Claims Act by producing contaminated infant formula at its Sturgis, Michigan, and Casa Grande, Arizona, facilities, failing to meet federal and state requirements between 2018 and 2022. Attorney General Dana Nessel emphasized that the settlement holds corporations accountable for ensuring product safety, especially for vulnerable populations.

Sep 15, 2026

Abbott Laboratories has agreed to pay $385 million to resolve claims related to an investigation into contamination at its Sturgis, Michigan baby formula plant, which is the largest in the U.S. This settlement addresses claims from a Justice Department lawsuit, relators, and state Attorneys General, following a 2022 recall that caused significant supply shortages. Abbott maintains that the settlement does not imply fault or liability, noting that tests of unopened products linked to the recall were negative for Cronobacter sakazakii.

Sep 15, 2026

Abbott Laboratories has agreed to pay nearly $385 million to settle federal allegations related to powdered infant formula produced at its Sturgis, Michigan facility. The government claimed Abbott failed to meet safety requirements, leading to potential microorganism contamination. While the settlement also covers products from an Arizona plant, Abbott denies any liability.

Sep 15, 2026

Abbott Laboratories has agreed to pay nearly $385 million to settle allegations that it knowingly sold infant formula manufactured in unsafe facilities. The settlement follows a 2022 recall of formulas from its Michigan plant, which was linked to bacterial infections in infants and contributed to a nationwide shortage. The Justice Department detailed unsanitary conditions at the plant, though Abbott did not admit liability.

Sep 15, 2026

Abbott Laboratories has agreed to pay over $384 million to settle U.S. Justice Department allegations regarding contaminated infant formula production at its Michigan and Arizona facilities. While this settlement resolves civil claims and closes a related criminal investigation, reducing some uncertainty, the company still faces ongoing litigation related to its infant formula business, including a $495 million jury award affirmed on appeal. Despite the cost, the settlement is financially manageable for Abbott, which continues to see growth in its broader medical-device, diagnostics, and pharmaceutical businesses.

Sep 15, 2026

Analysts have given Medtronic PLC (NYSE:MDT) an average "Moderate Buy" recommendation, with 19 buy ratings and nine hold ratings among 28 firms. The average 12-month price target is $103.92, exceeding the current share price of $93.87. The company recently surpassed quarterly earnings expectations, reporting $1.45 in adjusted EPS and $9.76 billion in revenue, and announced a quarterly dividend of $0.72 per share, yielding 3.1%.

Sep 15, 2026

Abbott Laboratories has agreed to pay $385 million to resolve allegations stemming from a 2022 infant formula contamination investigation that led to the closure of its largest plant. The agreement, announced by the Justice Department, resolves False Claims Act claims without an admission of fault from Abbott. Three Abbott employees who filed a whistleblower lawsuit will receive $69 million from the settlement.

Sep 15, 2026

Abbott Laboratories has agreed to pay $385 million to settle a Department of Justice (DOJ) lawsuit regarding contamination at its infant formula manufacturing plant. The settlement addresses allegations that the plant operated under unsanitary conditions, leading to a nationwide shortage and bacterial infections in infants, two of whom died. Abbott, however, maintains that there is no evidence directly linking its formula to the illnesses or deaths.

Sep 14, 2026

Abbott Laboratories has agreed to pay over $384 million to settle allegations related to contaminated infant formula, as announced by the U.S. Justice Department. This settlement addresses concerns regarding the safety of their infant formula products. The details were reported by Reuters on September 14, 2026.

Sep 14, 2026

Abbott Laboratories has agreed to pay over $384 million to settle allegations related to contaminated infant formula, as announced by the U.S. Justice Department. The settlement was reported on Monday, September 14, 2026. This action addresses claims regarding the safety of their infant formula products.

Sep 14, 2026

Abbott Laboratories has agreed to pay $385 million to settle federal and state lawsuits related to the safety of its powdered infant formulas, which were recalled in 2022 due to contamination allegations. While Abbott maintains no fault or liability, the settlement addresses claims that conditions at its Sturgis, Michigan plant led to Cronobacter sakazakii and Salmonella Newport infections in infants. This settlement follows another recent $670 million agreement regarding allegations that its formula for premature babies causes a dangerous intestinal disease.